Six Weeks Too Late? Praxbind Gets 2017 Medicare Boost But Not AndexXa
Executive Summary
User fee date for Portola's anticoagulant reversal agent is near, but not soon enough for Medicare's new technology payments in 2017 – while Boehringer's Praxbind gets in in time; BTG's Vistogard also gains the extra payments.
You may also be interested in...
Keeping Track: Janssen Gets A Breakthrough Therapy Status, FDA Awards Two Orphan Drug Designations, Portola Lands A CRL
The latest drug development news and highlights from our FDA Performance Tracker.
Key Clinical Data And Drug Approvals Expected In 2H 2016
As July is already upon us, Scrip takes a look at some of the more interesting clinical trial read-outs and drug approvals expected clinical trials due to report in the second half of the year.
Medicare Add-On Payments For Praxbind, Andexanet Under Consideration
Although few drugs have ever gotten the new technology designation, the two antidotes for excessive bleeding caused by anticoagulant treatments seem to have a good chance of being awarded added payments by CMS.